These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 21594787)

  • 1. Introduction to section III: biochemical methods to study CFTR protein.
    Amaral MD; Lukacs GL
    Methods Mol Biol; 2011; 741():213-8. PubMed ID: 21594787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction to section III: resources for CFTR research.
    Amaral MD
    Methods Mol Biol; 2011; 742():281-3. PubMed ID: 21547739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Turnover of the cystic fibrosis transmembrane conductance regulator (CFTR): slow degradation of wild-type and delta F508 CFTR in surface membrane preparations of immortalized airway epithelial cells.
    Wei X; Eisman R; Xu J; Harsch AD; Mulberg AE; Bevins CL; Glick MC; Scanlin TF
    J Cell Physiol; 1996 Aug; 168(2):373-84. PubMed ID: 8707873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners.
    Li C; Naren AP
    Pharmacol Ther; 2005 Nov; 108(2):208-23. PubMed ID: 15936089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro CFTR folding assays.
    Stidham RD; Wigley WC; Thomas PJ
    Methods Mol Med; 2002; 70():311-22. PubMed ID: 11917534
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients.
    Dray-Charier N; Paul A; Scoazec JY; Veissière D; Mergey M; Capeau J; Soubrane O; Housset C
    Hepatology; 1999 Jun; 29(6):1624-34. PubMed ID: 10347100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modelling approaches for cystic fibrosis transmembrane conductance regulator studies.
    Odolczyk N; Zielenkiewicz P
    Int J Biochem Cell Biol; 2014 Jul; 52():39-46. PubMed ID: 24735712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction to section I: overview of approaches to study cystic fibrosis pathophysiology.
    Clunes MT; Boucher RC
    Methods Mol Biol; 2011; 742():3-14. PubMed ID: 21547723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation.
    Cormet-Boyaka E; Jablonsky M; Naren AP; Jackson PL; Muccio DD; Kirk KL
    Proc Natl Acad Sci U S A; 2004 May; 101(21):8221-6. PubMed ID: 15141088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental paradigm for early features of cystic fibrosis.
    Larson JE; Cohen JC
    Pediatr Pulmonol; 2005 Nov; 40(5):371-7. PubMed ID: 15830387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cystic fibrosis transmembrane conductance regulator (CFTR) gene: mutations and clinical phenotypes].
    Schwartz M
    Ugeskr Laeger; 2003 Feb; 165(9):912-6. PubMed ID: 12661515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-nitrosoglutathione increases cystic fibrosis transmembrane regulator maturation.
    Zaman K; McPherson M; Vaughan J; Hunt J; Mendes F; Gaston B; Palmer LA
    Biochem Biophys Res Commun; 2001 Jun; 284(1):65-70. PubMed ID: 11374871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel.
    Seibert FS; Jia Y; Mathews CJ; Hanrahan JW; Riordan JR; Loo TW; Clarke DM
    Biochemistry; 1997 Sep; 36(39):11966-74. PubMed ID: 9305991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations.
    Alibakhshi R; Kianishirazi R; Cassiman JJ; Zamani M; Cuppens H
    J Cyst Fibros; 2008 Mar; 7(2):102-9. PubMed ID: 17662673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Misfolding of the cystic fibrosis transmembrane conductance regulator and disease.
    Cheung JC; Deber CM
    Biochemistry; 2008 Feb; 47(6):1465-73. PubMed ID: 18193900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CFTR regulation of ENaC.
    Donaldson SH; Poligone EG; Stutts MJ
    Methods Mol Med; 2002; 70():343-64. PubMed ID: 11917536
    [No Abstract]   [Full Text] [Related]  

  • 18. Cystic fibrosis and related diseases of the pancreas.
    Naruse S; Kitagawa M; Ishiguro H; Fujiki K; Hayakawa T
    Best Pract Res Clin Gastroenterol; 2002 Jun; 16(3):511-26. PubMed ID: 12079272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
    Pasyk S; Li C; Ramjeesingh M; Bear CE
    Biochem J; 2009 Feb; 418(1):185-90. PubMed ID: 18945216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixing cystic fibrosis CFTR with correctors and potentiators. Off to a good start.
    Elborn JS
    Thorax; 2012 Jan; 67(1):4-5. PubMed ID: 22058188
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.